Nektar Therapeutics blames former partner Eli Lilly for setbacks in the development of their atopic dermatitis drug, rezpegaldesleukin. The biotech alleges that Lilly miscalculated clinical data for the drug, leading to erroneous results and the halting of its development.
Nektar Therapeutics believes that Lilly's actions were motivated by a desire to favor a different atopic dermatitis drug it had acquired in a $1.1 billion deal. Nektar contends that these actions have significantly hindered the progress of rezpegaldesleukin, delaying its entry into Phase 2 studies for atopic dermatitis.
In the market for atopic dermatitis treatments, the dominant player is currently Dupixent, a biologic drug developed by Sanofi and Regeneron Pharmaceuticals. Nektar's rezpegaldesleukin aims to bring dosing and efficacy advantages compared to existing treatments, but its development has been delayed by the alleged actions of Eli Lilly.
Nektar Therapeutics believes that Lilly's actions were motivated by a desire to favor a different atopic dermatitis drug it had acquired in a $1.1 billion deal. Nektar contends that these actions have significantly hindered the progress of rezpegaldesleukin, delaying its entry into Phase 2 studies for atopic dermatitis.
In the market for atopic dermatitis treatments, the dominant player is currently Dupixent, a biologic drug developed by Sanofi and Regeneron Pharmaceuticals. Nektar's rezpegaldesleukin aims to bring dosing and efficacy advantages compared to existing treatments, but its development has been delayed by the alleged actions of Eli Lilly.
[
add
]
[
|
|
...
]